# A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries

> **NCT05214326** · — · COMPLETED · sponsor: **Sanofi** · enrollment: 187 (actual)

## Conditions studied

- Dermatitis Atopic

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05214326
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-18
- **Primary completion:** 2023-03-21
- **Final completion:** 2023-03-21
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05214326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05214326, "A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05214326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*